相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
Pascale Hubert et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Extracellular HMGB1 exacerbates autoimmune progression and recurrence of type 1 diabetes by impairing regulatory T cell stability
Jing Zhang et al.
DIABETOLOGIA (2020)
Turning up the heat on non-immunoreactive tumours: opportunities for clinical development
María Ochoa de Olza et al.
LANCET ONCOLOGY (2020)
Detection of immunogenic cell death and its relevance for cancer therapy
Jitka Fucikova et al.
CELL DEATH & DISEASE (2020)
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2019)
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Paola Bonaventura et al.
FRONTIERS IN IMMUNOLOGY (2019)
Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion
Linsen Ye et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Prospect and progress of personalized peptide vaccinations for advanced cancers
Shinjiro Sakamoto et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia et al.
LANCET ONCOLOGY (2016)
HMGB1 Enhances Immune Suppression by Facilitating the Differentiation and Suppressive Activity of Myeloid-Derived Suppressor Cells
Katherine H. Parker et al.
CANCER RESEARCH (2014)
HMGB1 in health and disease
Rui Kang et al.
MOLECULAR ASPECTS OF MEDICINE (2014)
Next-generation peptide vaccines for advanced cancer
Akira Yamada et al.
CANCER SCIENCE (2013)
HMGB1 in Cancer: Good, Bad, or Both?
Rui Kang et al.
CLINICAL CANCER RESEARCH (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
Shigeki Chiba et al.
NATURE IMMUNOLOGY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Immunogenic cell death and DAMPs in cancer therapy
Dmitri V. Krysko et al.
NATURE REVIEWS CANCER (2012)
Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity
Taro Kawai et al.
IMMUNITY (2011)
Knockdown of HMGB1 in Tumor Cells Attenuates Their Ability To Induce Regulatory T Cells and Uncovers Naturally Acquired CD8 T Cell-Dependent Antitumor Immunity
Zuqiang Liu et al.
JOURNAL OF IMMUNOLOGY (2011)
High-mobility group box 1 and cancer
Daolin Tang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2010)
分享论文
